A Study to Assess the Efficacy and Safety of PPC-06 (Tepilamide Fumarate)
Public ClinicalTrials.gov record NCT03421197. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, 24-Week Study to Assess the Efficacy and Safety of PPC-06 (Tepilamide Fumarate) Extended Release Tablets in Subjects With Moderate-to-Severe Plaque Psoriasis (AFFIRM)
Study identification
- NCT ID
- NCT03421197
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Dr. Reddy's Laboratories Limited
- Industry
- Enrollment
- 426 participants
Conditions and interventions
Conditions
Interventions
- PPC-06 400 mg QD Drug
- PPC-06 400 mg BID Drug
- PPC-06 600 mg Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 24, 2018
- Primary completion
- Mar 29, 2020
- Completion
- Mar 29, 2020
- Last update posted
- Mar 31, 2022
2018 – 2020
United States locations
- U.S. sites
- 74
- U.S. states
- 26
- U.S. cities
- 57
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site 144 | Glendale | Arizona | 85308 | — |
| Site 167 | Phoenix | Arizona | 85018 | — |
| Site 158 | Phoenix | Arizona | 85053 | — |
| Site 170 | Tempe | Arizona | 85283 | — |
| Site 157 | Bryant | Arkansas | 72022 | — |
| Site 125 | Rogers | Arkansas | 72758 | — |
| Site 133 | Fountain Valley | California | 92708 | — |
| Site 107 | Fremont | California | 94538 | — |
| Site 121 | Fresno | California | 93720 | — |
| Site 153 | Fullerton | California | 92835 | — |
| Site 176 | Los Angeles | California | 90057 | — |
| Site 178 | Los Angeles | California | 90057 | — |
| Site 182 | Los Angeles | California | 90057 | — |
| Site 156 | Murrieta | California | 92562 | — |
| Site 141 | San Diego | California | 92123 | — |
| Site 155 | Santa Rosa | California | 95405 | — |
| Site 137 | Clearwater | Florida | 33761 | — |
| Site 130 | Coral Gables | Florida | 33134 | — |
| Site 143 | Hialeah | Florida | 33012 | — |
| Site 145 | Hialeah | Florida | 33012 | — |
| Site 181 | Hialeah | Florida | 33012 | — |
| Site 149 | Miami | Florida | 33014 | — |
| Site 105 | Miami | Florida | 33144 | — |
| Site 174 | Miami | Florida | 33155 | — |
| Site 164 | Miami | Florida | 33175 | — |
| Site 123 | Miami | Florida | 33186 | — |
| Site 112 | Miramar | Florida | 33027 | — |
| Site 172 | New Port Richey | Florida | 34655 | — |
| Site 152 | Orange Park | Florida | 32073 | — |
| Site 154 | Pembroke Pines | Florida | 33028 | — |
| Site 110 | Sweetwater | Florida | 33172 | — |
| Site 150 | Tampa | Florida | 33609 | — |
| Site 113 | Tampa | Florida | 33624 | — |
| Site 132 | Marietta | Georgia | 30060 | — |
| Site 124 | Savannah | Georgia | 31406 | — |
| Site 122 | Nampa | Idaho | 83651 | — |
| Site 179 | Wheaton | Illinois | 60189 | — |
| Site 115 | Indianapolis | Indiana | 46256 | — |
| Site 171 | New Albany | Indiana | 47150 | — |
| Site 139 | Overland Park | Kansas | 66215 | — |
| Site 165 | Louisville | Kentucky | 40202 | — |
| Site 131 | Louisville | Kentucky | 40217 | — |
| Site 142 | Louisville | Kentucky | 40241 | — |
| Site 119 | Baton Rouge | Louisiana | 70808 | — |
| Site 126 | New Orleans | Louisiana | 70115 | — |
| Site 128 | Clinton Township | Michigan | 48038 | — |
| Site 129 | Fridley | Minnesota | 55432 | — |
| Site 111 | Kansas City | Missouri | 64114 | — |
| Site 109 | Omaha | Nebraska | 68114 | — |
| Site 127 | Las Vegas | Nevada | 89119 | — |
| Site 180- | Las Vegas | Nevada | 89148 | — |
| Site 103 | New York | New York | 10012 | — |
| Site 177 | New York | New York | 10075 | — |
| Site 104 | New York | New York | 10155 | — |
| Site 161 | Rochester | New York | 14623 | — |
| Site 146 | Stony Brook | New York | 11790 | — |
| Site 108 | High Point | North Carolina | 27262 | — |
| Site 116 | Wilmington | North Carolina | 28405 | — |
| Site 118 | Beachwood | Ohio | 44122 | — |
| Site 169 | Cincinnati | Ohio | 45236 | — |
| Site 114 | Johnston | Rhode Island | 02919 | — |
| Site 134 | Mt. Pleasant | South Carolina | 29464 | — |
| Site 100 | Rapid City | South Dakota | 57702 | — |
| Site 148 | Austin | Texas | 78745 | — |
| Site 160 | Bellaire | Texas | 77401 | — |
| Site 162 | Houston | Texas | 77004 | — |
| Site 102 | Houston | Texas | 77056 | — |
| Site 106 | San Antonio | Texas | 78229 | — |
| Site 101 | San Antonio | Texas | 78281 | — |
| Site 159 | Sugar Land | Texas | 77479 | — |
| Site 136 | Orem | Utah | 84058 | — |
| Site 166 | Norfolk | Virginia | 23507 | — |
| Site 135 | Burien | Washington | 98168 | — |
| Site 147 | Spokane | Washington | 99202 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03421197, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 31, 2022 · Synced Jul 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03421197 live on ClinicalTrials.gov.